In chemotherapy of ovarian cancer, cisplatin exposure boosted tumor immunogenicity via elevating calreticulin, MHC-I, antigen presentation, and T-cell infiltration through activating the cGAS/STING pathway (Grabosch et al., 2019). Here, STING1 is linked to neoplasm.